A purified serum glycopeptide from controls and cystic fibrosis patients. II. Comparison of their immunologic properties using monoclonal antibodies.
The immunogenic and antigenic properties of the cystic fibrosis glycopeptide and its normal counterpart were compared. BALB/c mice were immunized with either the cystic fibrosis glycopeptide or its normal counterpart and their spleen cells fused with X63NS1/1-Ag-4 (NS1) mouse myeloma cells. Four hybridization experiments (two with each glycopeptide) were performed in which different plating methods and screening assays were evaluated. Although an identical immunization procedure was used, 51 hybridoma cultures producing specific antibodies to the control glycopeptide and only 11 producing antibodies to the cystic fibrosis glycopeptide were obtained. Many of the monoclonal antibody preparations showed specificity toward the carbohydrate moiety of the glycopeptides and crossreacted immunologically with various glycoprotein preparations, whereas some were specific to the glycopeptides. The antibodies from the cloned hybridomas specific to the glycopeptide were used to compare serum fractions from controls and cystic fibrosis patients (10 samples in each group). Indistinguishable immunologic reactivity (antigenicity) between the controls and cystic fibrosis patients was demonstrated with the various monoclonal antibodies so far evaluated.